PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 2  of 53 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
STATISTICAL ANALYSIS PLAN SIGNATURE [CONTACT_310852] V1.0 ( Dated 05DEC2019) for Protocol N o. RPL554-CO-205. 
 
Name [CONTACT_310853]:    
  
  
 
Upon review of this document, t he undersigned app roves this ver sion of the Statistical Analysis 
Plan, authorizing that the conten t is acceptable for the report ing of this study. 
 
Name [CONTACT_310854]:    
  
  
[CONTACT_310832]:    
  
  
Approved By:   
[CONTACT_70821]: 
Company: 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 4  of 53 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382325] CIs Confidence Intervals
COPD Chronic Obstructiv e Pulmonary Disease 
CV Coefficient of Variation DMC Data Monitoring Committee ECG Electrocardiogram eCRF Electronic Case Report Form 
ENR All Patients Enrolled Set
E-RS
TM: COPD Evaluating Respi[INVESTIGATOR_310810] [ADDRESS_382326] 
MedDRA Medical Dictionary for Regulatory Activities MMRM Mixed Model for Repeated Measures Non-TEAE Non-treatment e mergent adverse event 
PD Pharmacodynamic 
PGAC Patient Global Assessment of Change 
PK Pharmacokinetic PPS Per-Protocol Set PT Preferred Term QTcF QT interval corrected for  heart rate using Friderica’s for mula 
RND All Patients Randomized Set SAE Serious Adverse EventSAF Safety Analysis Set SAP Statistical Analysis Plan 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 5  of 53 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382327]. George’s Respi[INVESTIGATOR_310811]-emergent Adverse Event 
WHO World Health Organization 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 6  of 53 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
TABLE OF CONTENTS 
1. INTRODUCTION .................................................. ............................................................... ........................... 9 
2. STUDY OBJECTIVES .............................................. ............................................................... .......................... 9 
2.1. PRIMARY OBJECTIVE ...................................................... ............................................................... .................................................... 9 
2.2. SECONDARY OBJECTIVE ...................................................... ............................................................... ............................................... 9 
2.3. EXPLORATORY OBJECTIVE ...................................................... ............................................................... ........................................ 10 
3. STUDY DESIGN .................................................. ............................................................... ........................... 10 
3.1. GENERAL DESCRIPTION ..................................................... ............................................................... ............................................. 10
3.2. SCHEDULE OF EVENTS ......................................................... ............................................................... ............................................ 11 
3.3. CHANGES TO ANALYSIS FROM PROTOCOL ....................................................... ............................................................... .............. 11 
4. PLANNED ANALYSES .............................................. ............................................................... ...................... 12 
4.1. DATA MONITORING COMMITTEE (DMC) ......................................................... .................................................. 12 
4.2. INTERIM ANALYSIS ....................................................... ............................................................... ................................................... 12 
4.3. FINAL ANALYSIS ....................................................... ............................................................... ....................................................... 12 
5. ANALYSIS SETS ................................................. ............................................................... ............................ 13 
5.1. ALL PATIENTS ENROLLED SET [ENR] ......................................................... ........................................................ 13 
5.2. ALL PATIENTS RANDOMIZED SET [RND] ......................................................... ................................................... 14 
5.3. FULL ANALYSIS SET [FAS] ......................................................... ............................................................... ....... 14 
5.4. PER-PROTOCOL SET [PPS] ......................................................... ............................................................... ...... 14 
5.5. SAFETY ANALYSIS SET [SAF] ......................................................... ............................................................... .... 14 
5.6. PK DATA SET [PKS] ......................................................... ............................................................... ............... 14 
6. GENERAL CONSIDERATIONS .......................................... ............................................................... .............. 14
6.1. REFERENCE START DATE AND PERIOD DAY ............................................................ ............................................................... ....... 14 
6.2. BASELINE ....................................................... ............................................................... ............................................................... ... 15 
6.3. RETESTS AND UNSCHEDULED VISITS ......................................................... ............................................................... ..................... 15 
6.4. WINDOWING CONVENTIONS .................................................... ............................................................... ..................................... 15 
6.5. STATISTICAL TESTS AND SUMMARIES....................................................... ............................................................... ...................... 16 
6.6. COMMON CALCULATIONS ................................................... ............................................................... ........................................... 16 
6.7. ACTUAL TREATMENT ...................................................... ............................................................... ................................................ 17 
6.8. SOFTWARE VERSION ........................................................ ............................................................... ............................................... 17 
7. STATISTICAL CONSIDERATIONS .................................... ............................................................... ................ 17 
7.1. ADJUSTMENTS FOR COVARIATES AND FACTORS TO BE INCLUDED IN ANALYSES ....................................................... .................. 17 
7.2. MISSING DATA ................................................... ............................................................... ............................................................. 17 
7.3. MULTIPLE COMPARISONS / M ULTIPLICITY ................................................... ............................................................... .................. 18 
7.4. EXAMINATION OF SUBGROUPS ...................................................... ............................................................... ................................ 18 
8. OUTPUT PRESENTATIONS .......................................... ............................................................... .................. 18 
9. DISPOSITION AND WITHDRAWALS ................................... ............................................................... ........... 18 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 7  of 53 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
 10. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ................ .......................................................... 18 
10.1. DERIVATIONS .................................................... ............................................................... .............................................................. 19 
10.2. MMRC............................................................ ............................................................... ............................. 19 
11. SURGICAL AND MEDICAL HISTORY................................... ............................................................... ............ 20 
12. PRIOR AND CONCOMITANT THERAPI[INVESTIGATOR_95240] ............... ....................................................... 20 
12.1. DERIVATIONS .................................................... ............................................................... .............................................................. 21 
13. STUDY TREATMENT EXPOSURE ...................................... ............................................................... .............. 21 
13.1. DERIVATIONS .................................................... ............................................................... .............................................................. 21 
14. STUDY TREATMENT COMPLIANCE .................................... ............................................................... ........... 22 
14.1. DERIVATIONS .................................................... ............................................................... .............................................................. 22 
15. E-DIARY COMPLIANCE ............................................ ............................................................... ..................... 22 
15.1. DERIVATIONS .................................................... ............................................................... .............................................................. 22 
16. EFFICACY OUTCOMES ............................................. ............................................................... ..................... 23 
16.1. PRIMARY EFFICACY ....................................................... ............................................................... .................................................. 23 
16.1.1.  Primary Efficacy Variables & Derivations ...................... ............................................................... ... 23 
16.1.2.  Primary Analysis of Primary Efficacy Variables ................ ...............................................................  23 
16.2. SECONDARY EFFICACY ....................................................... ............................................................... ............................................. 24 
16.2.1.  Secondary Efficacy Vari ables & Derivations .................... ............................................................... . 25 
16.2.2.  Analysis of Secondary Efficacy Variables ...................... ............................................................... .... 29 
16.3. EXPLORATORY EFFICACY ....................................................... ............................................................... .......................................... 29 
16.3.1.  Exploratory Efficacy Var iables & Derivations .................. ............................................................... . 30 
16.3.2.  Analysis of Exploratory Efficacy Variables .................... ............................................................... .... 30 
16.4. MISSING DATA METHODS FOR EFFICACY VARIABLES ...................................................... ............................................................ 31 
16.5. SENSITIVITY ANALYSIS FOR EFFICACY VARIABLES ...................................................... ............................................................... ..... 32 
16.6. INTERIM ANALYSIS ....................................................... ............................................................... ................................................... 33 
16.6.1.  Blinded ANCOVA analysis ....................................... ............................................................... .......... 33 
16.6.2.  Blinded MMRM analysis ......................................... ............................................................... ......... 34 
17. SAFETY OUTCOMES ............................................... ............................................................... ...................... 34 
17.1. ADVERSE EVENTS ......................................................... ............................................................... ................................................... 34 
17.1.1.  Severity ...................................................... ............................................................... ....................... 35 
17.2. LABORATORY EVALUATIONS .................................................... ............................................................... ....................................... 35 
17.2.1.  Laboratory Markedly Abnormal Criteria ......................... ............................................................... . 36 
17.3. ECG E VALUATIONS .................................................... ............................................................... ..................................................... 37 
17.3.1.  ECG Specific Derivations ...................................... ............................................................... ............. 37 
17.4. VITAL SIGNS .......................................................... ............................................................... .......................................................... 38 
17.4.1.  Vital Signs Markedly Abnormal Criteria ........................ ............................................................... ... 38 
17.5. PHYSICAL EXAMINATION ..................................................... ............................................................... ........................................... 39
17.6. PHARMACOKINETICS ............................................... ............................................................... ........................................................ 39 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 8  of 53 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382328] FOR RAW SCORE ASSIGNEMENT ......... ...................................................... 48 
APPENDIX 5. RAW SUMMED SCORE TO SCALE CONVERSION TABLE FOR EXAC T TOTAL SCORE ..................... 50 
APPENDIX 6. SGRQ-C ITEM WEIGHTS ............................... ............................................................... .............. 51 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 9  of 53 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
1. INTRODUCTION 
This document describes the ru les and conventions to be used in  the presentation and analysis of 
efficacy and safety as descri bed in Section 9 of the study prot ocol. It describe s the data to be 
summarized and analyzed, includi ng specifics of the statistical  analyses to be performed. 
This statistical analysis pla n (SAP) is base d on protocol versi on 5.0, dated 22nd July 2019. 
 
2. STUDY OBJECTIVES 
2.1. Primary Objective 
To investigate the bronchodilato r effect of different doses of RPL554 administered by [CONTACT_310833] k forced expi[INVESTIGATOR_3741] 1 s econd (FEV 1) (maximum over 3 
hours following dosing) at the final study visit (i.e., Week 4)  when administered twice daily to 
patients with moderate  to severe chronic obs tructive pulmonary disease (COPD) on a 
background of once-daily tiotropi[INVESTIGATOR_1890]. 
2.2. Secondary Objective 
x To investigate the bronchodilato r effect of RPL554 administered  by [CONTACT_310834] 0-3h FEV1 at Week [ADDRESS_382329] of RPL554 administered by [CONTACT_94274] o n change from baseline in  
morning trough FEV 1 at Week 4 
x To investigate the effects of  RPL554 on COPD symptoms, as measu red by [CONTACT_310835] 
(Evaluating Respi[INVESTIGATOR_310812] [E-RS™:COPD], St. Geo rge’s Respi[INVESTIGATOR_6004] [SGRQ-C], Baseline Dyspnea Index [BDI]/Transition  Dyspnea Index [TDI] 
and patient global assessment of c hange [PGAC]) 
x To investigate the bronchodilato r effect of RPL554 administered  by [CONTACT_310836]1, trough FEV1 and average AUC0-3h FEV1 at Weeks 1, [ADDRESS_382330] of RPL554 administered  by [CONTACT_310836]1, average AUC0-3h FEV1 and average AUC0-12h FEV1 at Day 1 
x To investigate the safety of R PL554 when adminis tered for 4 wee ks in patients with 
COPD, as measured by [CONTACT_310837] (AEs), laboratory tests, 12 -lead electrocardiograms 
(ECGs) and vital signs 
x To investigate the effect o f RPL554 on rescue albuterol use 
x To investigate the bronchodilato r effect of RPL554 administered  by [CONTACT_310838] 0-3h forced vital capacity (FVC) on D ay 1 and at Weeks 1 to 4, in av erage 
AUC 0-12 FVC on Day 1 and at Week 4 and in m orning trough FVC at Weeks 1  to 4. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 10  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382331] of RPL554 on inspi[INVESTIGATOR_14008] (IC ) on Day [ADDRESS_382332] (CAT) 
x To assess the effect of RPL554 on m orning symptoms and activity  limitation 
 
3. STUDY DESIGN 
3.1. General Description 
This is a Phase IIb, randomi zed, double-blind, placebo-controll ed dose ranging, parallel group 
study. A flow chart illustrating t he key components of the stud y is provided in Figure 1. 
 
Figure 1: Study Flow Chart 
 
 

PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 11  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382333] 
(spi[INVESTIGATOR_310813]- and post-f our puffs of albuterol). Eligib le patients will en ter a 14-day run- 
in and be dispensed open- label tiotropi[INVESTIGATOR_1890] (Sp iriva® Respi[INVESTIGATOR_96862]) a nd an electronic diary (e-diary) 
for recording symptoms, assessi ng rescue usage and confirming t wice daily dosing with study 
treatment. Starting t he day after Screening (Visit 1) patients will start ta king open-label 
tiotropi[INVESTIGATOR_1890] (Spi[INVESTIGATOR_35444]® Respi[INVESTIGATOR_96862]®) once daily in the morning. 
 
At Day 1 patients will be re-as sessed for eligibility according  to the Randomization Criteria, 
which can be found in Section 4.3 of  the study protocol. Eligib le patients will be stratified based 
on the reversibility to albuterol, a s determined at Screening ( “reversible”, “non-reversible”), then 
randomized to one of the five tr eatment groups within each reve rsibility stratum. After 
randomization, patients will take their tio tropi[INVESTIGATOR_310814] [ADDRESS_382334] dose of 
double-blind study treatment (RP L554 or placebo). Patients will  remain in the c linic for 12 hours 
to undergo serial spi[INVESTIGATOR_038] a nd other assessments. They will t hen take their second dose of 
study treatment in the  evening prior to clin ic discharge. Patie nts will return to the clinic for 3 
weekly visits. In between visits , patients will ta ke the study treatment twice a day (morning and 
evening) and tiotropi[INVESTIGATOR_310815] a day in the morning, in the same order as described above. 
 
Patients will be ins tructed to withhold st udy treatment, tiotro pi[INVESTIGATOR_310816]. Rescue medicati on will need to be withhold prior to the visit for at least 6 hours. 
 
Approximately 400 patients wit h COPD aged 40 to 80 years (inclu sive) will be randomized 
equally to receive RPL554 (four  possible doses) or placebo (Fig ure 1). Study treatment will be 
administered double-blind to minimize any potential bias in the  overall assessment of treatment 
effect and safety. 
3.2. Schedule of Events 
Schedule of events can be found in Section 6.0 of the study pro tocol. 
3.3. Changes to Analysis from Protocol 
No changes to the analysis outlines in the protocol are planned . 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 12  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
4. PLANNED ANALYSES 
A final analysis after database  lock is planned for this study.  
4.1. Data Monitoring Committee (DMC) 
There will be no data monitoring committee (DMC) for this study . 
4.2. Interim Analysis 
There will be no formal, unblinde d interim analysis for this st udy. To assess the plausibility of 
the assumptions in the sam ple size calculation, peak FEV 1, trough FEV 1, AUC 0-[ADDRESS_382335] devia tion has an increase  of 12% or less, th en there will be no revised sample 
size made. However, if the esti mated standard d eviation has an increase of 20% or more, a 
revised sample size estimation us ing the new standard deviation  and the previously assumed 
difference of [ADDRESS_382336] deviation will be 
between 12% and 20% then a decision t o review the sample size w ill be taken based on further 
examination of the data. 
4.3. Final Analysis 
All final, planned analyses iden tified in this SA P will be perf ormed by [CONTACT_310839] (and associated out put shells), database lock, 
analysis sets and unblinding of treatment. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 13  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
5. ANALYSIS SETS 
Agreement and authorization of pa tients included/ excluded from  each analysis set will be 
conducted prior to the un blinding of the study. 
Analyses will be performed for t he population sets described in  Table 1. 
 
Table 1: Use of the analysis set 
 
 All 
Patients 
Enrolled 
Set All Patients 
Randomized 
Set Full 
Analysi
s Set Per- 
Protocol 
Analysis 
Set Safety 
Analysis 
Set PK 
data 
Set 
Disposition of patients X     
Protocol deviations X     
Demographic and other baseline characteristics  X    
Medical history  X    
Prior and concomitant medication  X  X  
Treatment compliance and 
extent of exposure    X  
Efficacy: Primary endpoint   X X   
Efficacy: Secondary 
endpoints   X X   
Efficacy: Exploratory 
endpoints   X   
Sensitivity Analyses (incl. primary and selected 
secondary endpoints) *   X   
Safety    X  
Pharmacokinetic     X 
* ANCOVA analyses of the primary e ndpoint (change from baseline  FEV 1 to peak FEV 1 at 
Week 4), and key secondary endpoints (change from baseline FEV 1 to average AUC 0-12h FEV 1 at 
Week 4 and change from baseline in total E-RSTM:COPD score at Week 4). 
5.1. All Patients Enrolled Set [ENR] 
The all patients enrolled (ENR) set will contain all patients w ho provide informed consent for 
this study. Depending on the data  that is being analysed, patie nts will either be classified 
according to randomized treatment  or actual treatment received,  specified in the relevant section. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 14  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
5.2. All Patients Randomized Set [RND] 
The all patients randomized (RND) set will contain all patients  in the ENR set who are 
randomized to study treatment. For  analyses and displays based on the RND set, patients will be 
classified according to r andomized treatment. 
5.3. Full Analysis Set [FAS] 
The full analysis set (FAS) will contain all patients in the RN D set who have collected sufficient 
data after intake of study trea tment to compute any of the FEV 1 parameters (including peak 
FEV 1, trough FEV 1, AUC 0-12h FEV 1 and AUC 0-3h FEV 1) on at least one occas ion. Patients will be 
classified according to r andomized treatment. 
5.4. Per-Protocol Set [PPS] 
The per-protocol set (PPS) will contain all patients in the FAS  set who had no major protocol 
deviations considered to influe nce the treatment effect of RPL5 54. Protocol deviations will be 
agreed and documented prior t o database lock and unblinding. Pa tients will be classified 
according to randomized treatment. 
5.5. Safety Analysis Set [SAF] 
The safety analysis set (SAF) will contain all patients in the RND set who received at least one 
dose of study treatment . Patients will be c lassified according to actual treatment received. 
5.6. PK data Set [PKS] 
The pharmacokinetic (PK ) data set (PKS) w ill contain all patien ts in the RND set who have 
blood sampling performed and a quan titative value  of tiotropi[INVESTIGATOR_160045]/ or RPL554 concentration 
determined. Patie nts will be classified a ccording to actual tre atment. 
 
6. GENERAL CONSIDERATIONS 
6.1. Reference Start Date and Period Day 
The reference start date is de fined as the day of the first dos e of study treatment (RPL554 or 
placebo) and will appear in every listing where an assessment d ate or event date appears. 
If the date of the event is on or a fter the reference start dat e, then: 
Study Day = (date of event – r eference start date) + 1. 
If the date of the event is prio r to the reference start date, then: 
Study Day = (date of event  – reference start date).
In the situation where the event  date is partial or missing, St udy Day and any corresponding 
durations will appear partial  or missing in the listings, unles s otherwise stated. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 15  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382337] non -missing measurement taken prior 
to study treatment s tart date (including uns cheduled assessment s). In the case where the last 
non-missing measurement and the st udy treatment start date coin cide, the measu rement will be 
considered pre-baseline, unle ss time is present. If time of the  assessment is on or after the study 
treatment start date, then the assessment is not considered bas eline. AEs and medications 
commencing on the reference star t date will be c onsidered post- baseline. 
6.3. Retests and Unscheduled Visits 
Retests, reschedules and unsch eduled visits a re permitted at th e discretion of t he Investigator. 
 
All the data a vailable, including unsche duled or unplanned read ings will be presented within the 
patient listings, however only sch eduled readings will be used in the summaries. 
6.4. Windowing Conventions 
Each visit will have ±[ADDRESS_382338] com pleted the study, and t herefore the data will be presented a s per the visit 
reported in the database. 
For the discontinued patients End of Study (EOS) visit will be windowed to the corresponding 
visit, based on the study day, for que stionnaire, spi[INVESTIGATOR_310817] d rescue medication data. The rules 
for the windowing are as follows: 
- For questionnaires that only ha ppen at certain visits, windowin g will only be done for 
those corresponding visits. 
o For SGRQ-C and CAT: 
 Day 1 = Day 1 
 Week 2 = after day 1 and  up to and including day 16 
 Week 4 = after day 16 an d up to and including day 30 
o For TDI and PGAC: 
 Week 2 = after day 1 and  up to and including day 16 
 Week 4 = after day [ADDRESS_382339] of the questionnair es requiring windowing: 
 Day 1 = Day 1 
 Week 1 = after day 1 and  up to and including day 9 
 Week 2 = after day 9 and  up to and including day 16 
 Week 3 = after day 16 an d up to and including day 23 
 Week 4 = after day 23 and up t o and including day 30 
- For spi[INVESTIGATOR_310818], windowing will be 
done as per the corresponding visits. 
o Day 1 = Day 1 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 16  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
o Week 1 = after day 1 and  up to and including day 9 
o Week 2 = after day 9 and  up to and including day 16 
o Week 3 = after day 16 an d up to and including day 23 
o Week 4 = after day 23 an d up to and including day 30 
- For spi[INVESTIGATOR_310819],  windowing will be done for 
the corresponding visits. 
o For morning trough: 
 Week 1 = after day 1 and  up to and including day 9 
 Week 2 = after day 9 and  up to and including day 16 
 Week 3 = after day 16 an d up to and including day 23 
 Week 4 = after day 23 an d up to and including day 30 
o For AUC 0-12h: 
 Day 1 = Day 1 
 Week 4 = after day 1 and  up to and including day 30 
- For rescue medication data, wi ndowing will be done as per the c orresponding visits. 
o Day 1 = Day 1 
o Week 1 = after day 1 and  up to and including day 9 
o Week 2 = after day 9 and  up to and including day 16 
o Week 3 = after day 16 an d up to and including day 23 
o Week 4 = after day 23 an d up to and including day 30 
6.5. Statistical Tests and Summaries 
In general, unless stated other wise, continuous variables will be summarized using descriptive 
statistics (number  of patients, mean, standard deviation, media n, minimum and maximum 
values) and for categorical (no minal) variables, the number and  percentage of patients will be 
used. 
 
The default significance level will be 5%; confidence intervals  (CIs) will be 95% and all 
hypothesis testing will be done u sing two-sided alternative hyp otheses, unless otherwise 
specified. 
6.6. Common Calculations 
x Change from baseline: Test Valu e at Visit X – Baseline Value 
x Percentage change from baseline: 
Test Value at Visit X – Baseline Value
Baseline Value כ 100% 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 17  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
6.7. Actual Treatment 
Once the study unblinds, the patient ’s actual treatment will be  assigned based on the most 
frequent dose they have receive d throughout the study. The exte rnal vendor, Cenduit, will 
provide the Material List documen t after confirmation of a Data base Lock. This document will 
contain the kit numbers, which w ill be merged wit h the site dat a to the dosage that was dispensed 
at each visit. 
 
If a patient takes more than one  dose and the ratio of patient taking them is the same, then 
assigning actual treatment will follow the two rules: 
- RPL554 overrides Placebo 
- Higher dose overrides lower dose , i.e. if a patient takes for 5 0% of the time 1.5 mg dose 
and for another 50% of the time 0.75 mg dose, the n the patient would be assigned 1.5 mg 
as their actual treatment. 
6.8. Software Version 
All analyses will be conducted using SAS 9.4. 
 
7. STATISTICAL CONSIDERATIONS 
7.1. Adjustments for Covariates and Fa ctors to be Included in Analys es 
The following covariates and factor s will be used in the analys es. For details of t heir inclusion in 
the models, see the specific analysis section. 
x Fixed effects: treatment  (RPL554 0.375 mg, RPL554 0.75 mg, RPL5 54 1.5 mg, RPL554 3 
mg, Placebo), visit (Day 1, Weeks 1, 2, 3 and 4), visit*treatme nt, actual reversibility strata 
(reversible, non-reversible) 
x Random effect – patient 
x Covariate – baseline 
7.2. Missing data 
Missing data will only be imputed f or the calculation of averag e (AUC) effects for FEV 1 and 
FVC, which is described in Section 16.4. 
 
For the sensitivity analysis usi ng analysis of covariance (ANCO VA), missing data will be 
imputed using the last observation c arried forward (LOCF) metho d prior to analysis described in 
Section 16.4. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 18  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights rese rved. The contents of this document are confidential and propri etary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
7.3. Multiple Comparisons/ Multiplicity 
To address multiplicity in the analysis of the endpoints, stati stical testing of the  PD parameters 
and questionnaire scores will be  done in a hierarchical order. Firstly, the [ADDRESS_382340] rata. Reversible patients are those 
who are reversible to albuterol ( 12% and 200 mL increase in FEV 1), as defined in Section 5.[ADDRESS_382341] will be fin alized before 
database lock. 
 
10. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS 
Demographic data and ot her baseline characteristics will be lis ted for the ENR s et, with patients 
classified according to randomi zed treatment, a nd summarized fo r the RND set. 
  No statistical testing will be  carried out for demographic or  other baseline characteristics.  
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 19  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
The following demographic and othe r baseline characteristics wi ll be reported for this study: 
x Age (years) - calculated relative to date of consent 
x Age category (<65 years and 65 years) 
x Gender 
x Ethnicity 
x Race 
x Height (cm) 
x Weight (kg) 
x Body mass index (BMI) (kg/m2) 
x Reversibility status (reversib le or non-reversible) – ,planned and actual 
x Modified Medical Research Counc il (mMRC) questionnaire scores 
x Pre- and post-bronchodilator FEV 1 (both in litres and in percenta ge of predicted normal) 
x Post-bronchodilator FEV 1/FVC
x FEV 1 actual reversibility (in m L and as a percentage)
x Time since initial diagnosis of COPD (years) 
x Chronic Bronchitis (yes/no) 
x Smoking status (current smoker (yes/no), number of packs per da y, number of years 
smoking, and smoking exposure in pack-years) 
10.1. Derivations 
x BMI (kg/ m2) = weight (kg)/ height (m)2 
xTime since initial diagnosis of COP D = (date of consent - date first diagnosed)/ 365.25 
x Smoking exposure (pack-years) =  number of packs per day * numbe r of years smoking 
 
Reversibility status is calcu lated based on pre- dose and post-d ose FEV 1 values taken at 
Screening. If patient has increase of 12% and 200mL then patient is reve rsible, else patient is 
non-reversible. 
Actual reversibility strata w ill be decided on the value calcul ated pre-rounding, however rounded 
reversibility values will be pres ented in the outputs. See Appe ndix 3 for the rounding rules that 
are used by [CONTACT_310840]. 
10.2. mMRC 
Modified Medical Research Counc il (mMRC) questionnaire is used to assess a patient’s level of 
breathlessness and the  score will be listed. T he scores range f rom 0 to 4, with the following 
definitions: 0 = “I only get breathless w ith strenuous exercise”, 
1 = “I get short of breath whe n hurrying on the level or walkin g up a slight hill”, 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 20  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
2 = “I walk slower than people of  the same age on the level bec ause of breathlessness, or I have 
to stop for breath when walk ing on my own pace on the level”, 
3 = “I stop for breath after w alking about 100 meters or after a few minutes on the level”, 
4 = “I am too breathless to leave the house, or I am breathless  when dressing or undressing”. 
 
11. SURGICAL AND MEDICAL HISTORY 
Surgical and Medical History i nformation will be  listed and sum marized for the ENR set. 
x Surgical History will be coded us ing the Medical Dictionary for  Regulatory Activities 
(MedDRA) central coding dictionary, Version 22.0. 
Data captured on the ‘Surgical P rocedure History’ page of the e lectronic case report 
form (eCRF) will be presented by S ystem Organ Class (SOC) and P referred Term 
(PT). 
x Medical History will be coded us ing the MedDRA central coding d ictionary, Version 22.0. 
Medical History conditions are de fined as those conditions whic h stop prior to or at 
Screening. 
Concomitant illnesses are iden tified as “Ongoing” at Screening.  
Data captured on the ‘Medical Hi story’ page of the eCRF will be  presented by [CONTACT_16430]. 
x Patients with multiple  events within a SOC /PT will only be coun ted once for that category. 
 
12. P RIOR AND CONCOMITANT THERAPI[INVESTIGATOR_310820] (WHO) 
drug code and summari zed by [CONTACT_310841] (Anatomical Th erapeutic Chemical 
Classification System (ATC) leve l 2). Potential therapeutic sub groups include ICS, LABA, 
LAMA or combinations thereof, wh ich are defined in a separate s preadsheet provided by [CONTACT_310842]. Prior medications will be listed f or ENR set with patients clas sified according to randomized 
treatment and summarize d for the RND set . C oncomitant medicati ons will be listed for ENR set 
with patients classified accordi ng to actual treatment received  and summarized for the SAF set. 
 
See Appendix [ADDRESS_382342] case; i.e. concomitant. 

PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 21  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
 x ‘Prior’ medications are medicati ons which started prior to the first dose of study treatment 
and stopped prior to or on the f irst dose of study treatment. 
x ‘Concomitant’ medica tions are defined as medications with onset  dates on or after the first 
dose of study treatment and on or be fore last dose of study tre atment, or medic ations with 
onset dates prior to first dose  of study treatment without a st op date or with a  stop date 
after first dose of study treatment. 
x ‘Post treatment’ medications are  defined as medications with an  onset date after the date of 
last dose of study treatment. 
 
Patients taking COPD medications  prior to the study will be lis ted by [CONTACT_1728] c lass for the 
ENR set, classified according t o randomized treatment, and summ arized by [CONTACT_310843]. 
Patient with multiple medications within an ATC level/therapeut ic subgroup will only be 
counted once for that level. 
12.1. Derivations 
Time since first diagnosed with C OPD = (Date of informed consen t – Date of COPD first 
diagnosed + 1) / 365.25. 
 
13. STUDY TREATMENT EXPOSURE 
Exposure to study treatment will be  presented for the SAF set. 
 
The date of first and last study t reatment admin istration will be taken from the e-Diary entry. 
The number of vials dispensed and r eturned will be taken from “ Drug Accountability” page in 
the eCRF. 
13.1. Derivations 
The RPL554 exposure will be calculated as: 
 
Duration of exposure (in da ys) to study treatment: 
(stop date – start date) +1 
 
Total exposure (in mg): (Number of vials dispensed - Num ber of vials returned) x Conten t of each vial in mg 
 
The mean duration of exposure i n days and the mean exposure in mL will be summarized by 
[CONTACT_1570]. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 22  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
14. STUDY TREATMENT COMPLIANCE 
Compliance to study treatment a nd tiotropi[INVESTIGATOR_310821]. 
14.1. Derivations 
Treatment compliance will be  summarized by [CONTACT_121610] 2  ways: 
x 100*((total number of vials disp ensed – total number of vials r eturned)/ (expected number 
of vials to be taken during the study)) 
x Drug intake as recorded in the e-d iary: percent of ‘yes’ respon ses. The denominator is the 
number of records for which t he patient provided an answer (Yes  or No) to drug intake 
questions (morning and eve ning) in the e-diary. 
 
15. E-DIARY COMPLIANCE 
Compliance to e-diary will be s ummarized and lis ted for the SAF . 
15.1. Derivations 
E-diary compliance for study tr eatment will be summarized by [CONTACT_64240], for the duration 
of the treatment, as per the following: 100*((total number of e-diary ent ries for study treatment)/ (ex pected number of e-diary entries 
for study treatment during the study)) 
Each patient should have a morni ng and evening dose, which shou ld be recorded in the e-diary, 
including the dosing at site vi sits, however only dosing not at  the site visit will  be included in the 
compliance calculation. At Wee k 4 visit there should only be mo rning dose recorded. 
 
Number of e-diary entries will be calculated as per the followi ng: 
[(reference end date – referenc e start date) *2 – 1 evening dos e] – expected number of CRF 
entries The [ADDRESS_382343] completed the study. I n cases where patient discontin ues early the following strategy 
explained below will be used. 1. Count how many entries there are  in the “Drug Exposure” CRF dat aset. 
2. Select how many site visits pa tient should have  based on the fo llowing window for each 
visit: 
a. Calculate reference end day = reference end date – reference st art date +1 
b. 0 site visits if reference end day is missing 
c. 1 site visit if 1 <= reference end day <= 7 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 23  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
d. 2 site visits if 8 <= reference end day <= 14 
e. 3 site visits if 15 <= reference end day <= 21 
f. 4 site visits if 22 <= reference end day 
3. Choose the minimum number between points 1 and 2. 
 
16. EFFICACY OUTCOMES 
16.1. Primary Efficacy 
16.1.1. Primary Efficacy Var iables & Derivations 
The primary endpoint is the change from baseline FEV 1 to peak FEV 1 (maximum value 
following dose during the first 3 hour s) at Week 4 (after 4 wee ks of treatment). 
16.1.2.  Primary Analysis of Prima ry Efficacy Variables 
Peak FEV [ADDRESS_382344] the hypothesis t hat there is a difference between 
different dose levels of study tr eatment (RPL554) in comparison  with placebo, all administered 
by [CONTACT_310844][INVESTIGATOR_1890]. The change from baseli ne FEV 1 to peak FEV 1 will be 
compared between the treatments  using a mixed model for repeate d measures (MMRM) with 
fixed effects for treatment, vis it and treatment by [CONTACT_310845], patient as random effect and 
baseline as covariate. An unstruc tured covariance structure wil l be used to model the within- 
patient errors. If the model  does not converge a compound symme try covariance str ucture will be 
used. Kenward-Roger method will be  used to estimate  the model d egrees of freedom. 
 
Treatment comparisons will be s ummarised using mean effect diff erences with 95% CI and 
associated 2-sided p-values. Firstly, RPL554 treatments will  be compared to placebo using a closed testing procedure. The 
testing will begin with the highe st dose (3 mg) compared to pla cebo. If found statistically 
significant then the lower dos e (1.5 mg) will be compared to pl acebo. If found significant then 
the next lower dose will be com pared to placebo until either al l doses are compared to placebo, 
or a result is found to be non-signi ficant and therefore the co mparison ends. Secondly, the doses 
will be compared in a pairwise fashion as shown in Table 2, bel ow. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 24  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
Table 2: Pairwise comparison between the RPL554 treatment group s: 
 
RPL554 dose  
 
 
 
0.[ADDRESS_382345] squares mean change from basel ine FEV 1 to peak FEV 1 for Day 
1, Weeks 1 to 4 (based on the MMRM analysis) will be created. 
16.2. Secondary Efficacy 
The secondary efficacy endpoints include: 
x Change from baseline FEV 1 to average AUC 0-3h FEV 1 on Day 1 and at Weeks 1 to 4 
x Change from baseline FEV 1 to average AUC 0-12h FEV 1 on Day 1 and at Week 4 
x Change from baseline FEV 1 to peak FEV 1 on Day 1 and at Weeks 1 to 3 
x Change from baseline FEV 1 to morning trough FEV 1 at Weeks 1 to 4 
x Change from baseline (i.e., mea n over the last 7 days of run-in ) to the mean weekly values 
over Weeks 1 to 4 in COPD sympto ms, as measured by [CONTACT_310835] (E-RSTM:COPD) 
x Change from baseline in the SGR Q-C questionnaire at Weeks 2 and  4 
x TDI questionnaire at Weeks 2 and 4 
x PGAC questionnaire at Weeks 2 and 4 
x Change from baseline (i.e., mea n over the last 7 days of run-in ) to the mean weekly values 
over Weeks 1 to 4 in the number of  puffs of rescue medication 
x Change from baseline FVC to p eak FVC on Day 1 and at Week 4 
x Change from baseline FVC to average AUC 0-3h FVC on Day 1 and at Week 4 
x Change from baseline FVC to average AUC 0-12h FVC on Day 1 and at Week 4 
x Change from baseline FVC to m orning trough FVC at Weeks 1 to 4 
x Proportion of patients w ith an improvement from baseline in SGR Q-C total score of 4 or 
more 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 25  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
x Trough plasma concentration of tiotropi[INVESTIGATOR_310822] 1 and at Week 2, and trough plasma 
concentration of RPL554 at Week 2 
x Safety and tolerability: 
o Continuous monitoring of AEs 
o Laboratory safety tests (hema tology, blood chemistry and urinal ysis) 
o 12-lead ECG (including the QT inte rval corrected for heart rate  using Friderica’s 
formula (QTcF) and heart rate) , supi[INVESTIGATOR_32832] (blood press ure and pulse rate) 
16.2.1.  Secondary Efficacy Variables & Derivations 
[IP_ADDRESS].  PULMONARY FUNCTION TESTS 
[IP_ADDRESS].1.         SPI[INVESTIGATOR_310823] (FEV 1 and FVC) will be performed at Sc reening and the following time points 
during each treatment:
x Day 1 and Week 4 (End of Study):  30 minutes pre-dose; [ADDRESS_382346]-dose. 
x Week 1 – Week 3: 30 minutes pre-dose; [ADDRESS_382347] reading from each time poi nt will be used in all summar ies and analyses. Each 
measurement will be graded ba sed on the quality of the measurem ent. Grades “Acceptable” and 
“Borderline Acceptable” will be used in the analyses, as these will indicate usable 
measurements. Grade “Unaccepta ble” will not be used in the anal ysis, as the measurement will 
be identified a s poor quality. 
 
Morning trough FEV [ADDRESS_382348] value collecte d prior to the morning dose. 
Peak, average and trough FEV 1 and FVC will be summarized as actual value and change from 
baseline FEV 1 and FVC (e.g. change from baseline FEV 1 to peak/average/trough FEV 1). 
[IP_ADDRESS].2.         AUC 0-T 
The average effect will be cal culated as the AUC divided by [CONTACT_310846] (for example, 12 hours for AUC 0-12h or 3 hours for AUC 0-3h). AUC will be calculated 
using the trapezoidal method, as follows: 
 
ܥܷܣ = 1 σ݊െ1(ܶെ ܶ()ܥ + ܥ ) 
2 ݅=1 ݅+1 ݅ ݅+1 ݅ 
 
Where T i is the ith time value, C i is the ith concentration value , n is the number of time values.  
The change from the baseline FEV 1 to average FEV 1 (AUC) will be summa rised and analysed.
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 26  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382349] measureme nt for the calculation of the AU C is missing, then the AUC will 
not be calculated. 
[IP_ADDRESS].  DIARY DATA 
[IP_ADDRESS].1.         E-RSTM: COPD 
Evaluating Respi[INVESTIGATOR_696] S ymptoms for COPD (E-RSTM: COPD) data will be collected within 
EXACT-PRO questionnaire (cons isting of 14 questions), as shown in the Appendix 4. Please 
note that items 3, 8, 9, 10, [ADDRESS_382350] separate scoring in structions, namely with the same 
raw score being assigned to several answer options. E-RSTM: COPD consists of 11 questions, 
with subdomains of: Breathle ssness, Cough and Sputum, and Chest  Symptoms. This data will be 
collected everyday throughout  the duration of the study. 
Calculating the score 
E-RS subdomains: 
x Breathlessness – items 7, 8, 9, 10 a nd 11 (score range: 0-17) 
x Cough and Sputum – items 2, 3 and 4 ( score range: 0-11) 
x Chest Symptoms – items 1, 5 and 6 (score range: 0-12) 
Total and subdomain scores are de rived weekly as the mean over total number of days between 
previous visit (inclusive) a nd the following visit, using only days where data was recorded. For 
the last visit, when pa tient completes the  study the derivation  will use days between previous 
visit (inclusive) and the follo wing/last visit (inclusive). Bas eline is the mean over the [ADDRESS_382351]-PRO tot al score in the table describ ed in the Appendix 5. 
 
E-RS subdomain score is calculated as the sum from the relevant  questions. 
[IP_ADDRESS].2.         SGRQ-C 
St. George’s Respi[INVESTIGATOR_310824] – COPD sp ecific (SGRQ-C)  is a questionnaire consisting 
of [ADDRESS_382352] 7 questions and i s related to the 
Symptoms subdomain. The remaini ng 7 questions are in Part 2, wh ich are related t o the Activity 
and Impacts subdomains. Each po ssible answer to each question h as a weight assigned described 
in the Appendix 6. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 27  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
Calculating the score 
Subdomains: 
x Symptoms – items 1 to 7 
x Activity – items 9 and 12 
x Impacts – items 8, 10, 11, [ADDRESS_382353] missing items in the 
questionnaire, as the data is co llected in the e-diary which do esn’t allow patients to skip between 
items. 
 
 
݁ݎ݋ܿܵ =  100 כ ݉ݑܵ  ݂݋ ݏݐ݄݃݅݁ݓ  ݉݋ݎ݂  ݈݈ܽ ݁ݒ݅ݐ݅ݏ݋݌  ݏ݉݁ݐ݅  ݊݅ ݐ݄ܽݐ  ݐ݊݁݊݋݌݉݋ܿ  
 
݉ݑܵ  ݂݋ ݉ݑ݉݅ݔܽ݉  ݏݐ݄݃݅݁ݓ  ݎ݋݂ ݏ݉݁ݐ݈݈݅ܽ  ݊݅ ݐ݄ܽݐ  ݐ݊݁݊݋݌݉݋ܿ  
 
The total score is calculated similarly 
 
 
݁ݎ݋ܿܵ = 100 ݁ݎ݅ܽ݊݊݋݅ݐݏ݁ݑݍݐ݄ܽݐ݊݅ݏ݉݁ݐ݅݁ݒ݅ݐ݅ݏ݋݌݈݈ܽ݉݋ݎ݂ݏݐ݄݃݅݁ݓ݂݋݉ݑܵכ 
 
݉ݑܵ  ݂݋ ݉ݑ݉݅ݔܽ݉  ݏݐ݄݃݅݁ݓ  ݎ݋݂ ݈݈ܽ ݏ݉݁ݐ݅  ݊݅ ݐ݄ܽݐ  ݁ݎ݅ܽ݊݊݋݅ݐݏ݁ݑݍ  
 
The higher the score the more  severe impact of COPD on patient’ s life. 
[IP_ADDRESS].3.         BDI/TDI 
BDI and TDI are questionnaires that focus on three subdomains: Functional impairment, 
Magnitude of task and Magnitude of  effort. BDI is collected at baseline (Day 1) and TDI is 
collected post-baseline (Weeks 2 and 4). 
 
Subdomain score is calcu lated as the sum from the related quest ions. 
Total score is calculated as t he sum of the subdomain scores. 
 
If at least one of the scores i s missing, then total score is s et to missing. 
[IP_ADDRESS].4.         PGAC 
Patient Global Assessm ent of Change (PGAC) is a single question  assessment to determine 
whether patients have noticed a  change in their breathing since  the start of the study. 
[IP_ADDRESS].5.         CAT 
CAT is designed to assess further the COPD symptoms. There are [ADDRESS_382354] of COPD on patient’s life. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 28  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
[IP_ADDRESS].  COPD E XACERBATIONS 
Patients with at least one AE meeting both the following criter ia will be include d in the analysis 
of exacerbations: 
x MedDRA LLT = ”COPD exacerbation” 
x Use of a systemic ste roid (ATC2=H02) at or  after the AE date of  onset and before the end 
date, lasting for at least 3 days 
[IP_ADDRESS].  RESCUE MEDICATIONS 
Rescue medication use will be  presented for the FAS set. 
 
Baseline use of rescue medica tion is the mean over the last 7 d ays of run-in phase, using only 
days where data was recorded: 
 
݉ݑܵ  ݎܾ݁݉ݑ݂݊݋  ݂݋ ݏ݂݂ݑ݌  ݊݁݇ܽݐ  
ݏݕܽ݀  ݀݁݀ݎ݋ܿ݁ݎ  
 
Use of medication per visit is calculated as the mean use daily  over total number of days between 
previous visit (inclusive) a nd the following visit, e.g. Week 1  is defined as the period between 
Visit 2 and Visit 3, calculate d only based on the days data was  recorded/verified. For the last 
visit, when patient completes t he study the derivation will use  days between previous visit 
(inclusive) and the followi ng/last visit (inclusive).
If less than [ADDRESS_382355] expected visit. 
This will be documented i n the “Rescue Medica tion” page of the eCRF, as well as in the “Rescue 
Medication Use” diary entry. 
 
The rescue medication use will  be confirmed in the diary using the following rules: 
1. If patient has put in rescue medi cation use then analyse as exp ected 
2. If patient has not put in rescue medication use, then to confir m that there was no diary 
compliance issue, or IT issue , question “No Rescue Medication C onfirmation” will be 
checked to make sure it is filled in correctly. 
3.  If patient has not put in rescu e medication use and question “ No Rescue Medication 
Confirmation” was not f illed in correctly t hen this will be tre ated as diary compliance or 
IT issue and therefore this da y will not be used a s the day rec orded for the weekly means 
calculation. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 29  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights rese rved. The contents of this document are confidential and propri etary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
16.2.2. Analysis of Secondary Efficacy Variables 
PD parameters (trough FEV 1, peak FEV 1, FEV 1 AUC 0-T, trough FVC, peak FVC and FVC 
AUC 0-T), rescue medication, average weekly E-RSTM:COPD, SGRQ-C, T DI and PGAC scores 
will be analysed using an MMRM a pproach, as described in Sectio n 16.1.2 for the primary 
endpoint. The change from baselin e will be analysed for all end points except TDI and PGAC. 
The BDI will be used as baseline for TDI. The baseline term wil l not be included in the MMRM 
analysis of PGAC. 
For exploratory purposes, the  subdomain scores of E-RSTM:COPD and SGRQ-C will also be 
summarised and analyse d in the same way. 
A plot of the mean change from baseline FEV [ADDRESS_382356] squares mean s change from baseline to total  score E-RS over time will be 
presented (based on the MMRM analysis). 
 
Furthermore, an analysis of t he proportion of res ponder patient s, with an improvement from 
baseline in SGRQ-C total score  of 4 or more, will  be summarised  by [CONTACT_310847]. The model for each visi t will include randomised 
treatment groups and actual revers ibility strata as factors. Pa tients with a missi ng response, either 
due to withdrawal or that the SG RQ-C questionnaire was not fill ed in properly, w ill be assumed 
to be a non- responder. A bar chart of the percentage  of responders at each visit will also be presented by [CONTACT_6490]. 
 
Total score will be used for the  TDI analysis; BDI and TDI tota l and subdomain scores will be 
listed. 
 
The secondary efficacy analyses (excluding the PK summaries) wi ll be performed on the FAS 
set. The PK results will be s ummarised for the PKS set. 
The analyses of the secondary s afety endpoints are described in  Section 17. 
16.3. Exploratory Efficacy 
The exploratory endpoints include: 
x Change in peak FEV 1 from Day 1 to Week 4 
  x   Change in average AUC 0-12h FEV 1  from Day 1 to Week 4  
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 30  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
 x Change from baseline in IC on Day 1 and at Week 4 
x Change from baseline in the C AT questionnaire at Weeks 2 and 4 
x Change from baseline (i.e. mea n over the last 7 days of run-in)  to the mean weekly values 
over Weeks 1 to 4 in morning symptoms 
x Change from baseline (i.e. mea n over the last 7 days of run-in)  to the mean weekly values 
over Weeks 1 to 4 in morning activity limitations 
x Proportion of patients w ith an improvement from baseline in CAT  total score of 4 or more 
16.3.1.  Exploratory Efficacy Var iables & Derivations 
Peak FEV 1 is defined in Section [IP_ADDRESS].1. AUC 0-T will be derived as de tailed in Section 
[IP_ADDRESS].2. 
[IP_ADDRESS].  DIARY DATA 
[IP_ADDRESS].1.         MORNING SYMPTOMS 
Morning symptoms are scored ba sed on the overall COPD symptom s everity in the early 
morning before the first dose of  COPD treatment. COPD symptoms include: cough, wheezing, 
shortness of breath, tightness in chest, chest congestion, diff iculty bringing up phlegm. Patients 
will be asked to rate their symptoms between 0 to 4, 0= ”no sym ptoms” and 4= ”severe 
symptoms”. 
 
Weekly means are calculated as  per method detailed in section 1 [IP_ADDRESS].1. 
[IP_ADDRESS].2.         MORNING ACTIVITY LIMITATIONS 
Morning activity limitations are  scored based on the activity l imitations in the early morning 
before the first dose of COPD tr eatment. Morning activities wil l include: showering, making 
breakfast, dressing, etc . Patients will be a sked to rate their activity limitations between 0 to 4, 0 
=” I do not have any difficulty in pe rforming” and 4 =”I have g reat difficulty in performing”. 
 
Weekly means are calculated as  per method detailed in section 1 [IP_ADDRESS].1. 
16.3.2. Analysis of Exploratory Efficacy Variables 
Peak FEV 1, CAT scores, morning symptom s and morning ac tivity limitations  will be analysed 
using an MMRM approach, a s described in Section 16.1.2. 
 
Due to AUC 0-12h FEV 1 only being derived for Day 1 a nd Week 4, an ANCOVA analysis of the 
change from baseline will be pe rformed with fixed effects for t reatment and actual reversibility 
strata, and baseline as a covariat e. Each measurement will be g raded based on the quality of the 
measurement. Grades “Acceptable” and “Borderline Acceptable” wi ll be used in the analyses, as 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 31  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
these will indicate usable measurements. Grade “Unacceptable” w ill not be used in the analysis, 
as the measurement will be  identified as poor quality. 
 
Total score data will  be used for the CAT questionnaire analysi s. 
An analysis of the proportion of  patients with a n improvement f rom baseline in CAT total score 
of [ADDRESS_382357] square  means change from baseline in 
total score over time  will be presented (based on the MMRM anal ysis). 
 
Due to IC only being collecte d on Day [ADDRESS_382358]-dose, an ANCOVA anal ysis of the change from ba seline (Day 1, 30 minutes 
pre-dose) to remaining 3 timepoint s will be performed with fixe d effects for treatment and actual 
reversibility strata, and baseline as a covariate. Each measure ment will be gra ded based on the 
quality of the measurement. Grade s “Acceptable” and “Borderline  Acceptable” will be used in 
the analyses, as these will indicate usable measurements. Grade  “Unacceptable” will not be used 
in the analysis, as the measur ement will be identified as poor quality. 
16.4. Missing Data Methods for  Efficacy Variables 
Data for calculation of avera ge (AUC) effects for FEV 1 will be imputed if the pre-dose is not 
missing. This will be done us ing the following method: 
x ‘bounded’ missing data will use in terpolation through the trape zoidal method described in 
section [IP_ADDRESS].2, 
x ‘unbounded’ missing data w ill not be imputed 
o If last measurement is missing, t hen the AUC will be calculated  up to the point 
where data is not missing, however  if two or more last measurem ents will be 
missing, then the AUC will  be set to missing. 
o If first measurement is missi ng, the AUC will not be calculated  and set to 
missing. 
For the analysis of responder  on SGRQ-C and CAT missing respons es will be treated as 
indicating non-responders in the analysis. All other missing data, including f or when pre-dose is missing,  will not be imputed. 
For the sensitivity and interim analysis missing data will be i mputed using LOCF method. In 
cases where patient discontinue s early and has spi[INVESTIGATOR_310825], the 
following strategy explaine d below will be used. 
1. Check the visit day at which EOS vi sit was performed against th e following window for
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 32  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
each visit: 
a. Day 1 = Day 1 
b. Week 1 = after day 1 and  up to and including day 9 
c. Week 2 = after day 9 and  up to and including day 16 
d. Week 3 = after day 16 an d up to and including day 23 
e. Week 4 = after day [ADDRESS_382359] s pi[INVESTIGATOR_310826], or cases of missing da ta for patients who did not di scontinue early, LOCF will be 
applied in the usual manner. 
16.5. Sensitivity analysis for Efficacy Variables 
Sensitivity analyses will be done for the pr imary endpoint (cha nge from baseline FEV 1 to peak 
FEV 1 at Week 4) and for key secondar y endpoints (change from baselin e FEV 1 to average 
AUC 0-12h FEV 1 at Week 4, and change from baseline in total E-RSTM:COPD score at Week 4). 
An ANCOVA approach will be used t o compare trea tment groups, wi th fixed factors for 
treatment and actual reversibility strata , and the baseline res ult as a covariate. RPL554 treatments 
will be compared to placebo and to e ach other, as described in Section 16.1.2. 
As a sensitivity analysis, the pr imary analysis (i.e. MMRM) of the efficacy endpoints described 
above will be repeate d on the PPS set. 
 
Furthermore, an analysis of t he proportion of patie nts with an improvement from baseline in 
SGRQ-C total score of [ADDRESS_382360] 
known responder status (LOCF). Any missing data post-ba seline will be imputed using the LOCF m ethod described in Section 
16.4. 
 
Sensitivity analysis, with resp ect to impact of rescue use duri ng clinic visits, will only be 
performed if at least one patient  is excluded from this analysi s due to taking rescue medication 
within [ADDRESS_382361] 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 33  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382362],  will be repeated for each of the 
following scenarios. 
x Calculation 1 – unknown sample si ze (per treatment group), know n detectable treatment 
difference (93 mL) and power (80%) 
x Calculation 2 – unknown power (%), know n detectable treatment d ifference (93 mL) and 
sample size (73 per treatment group) 
x Calculation 3 – Unknown detectable t reatment difference (mL), k nown power (80%) and 
sample size (73 per treatment group) 
The ANCOVA analysis will be pe rformed on the following endpoint s. The MMRM analysis will 
be performed for the  first endpoint only: 
x Change from baseline FEV 1 to peak FEV 1 at Visit 6 
x Change from baseline FEV 1 to average AUC 0-3h FEV 1 at Visit 6 
x Change from baseline FEV 1 to average AUC 0-12h FEV 1 at Visit 6 
x Change from baseline FEV 1 to morning trough FEV 1 at Visit 6 
16.6.1.  Blinded ANCOVA analysis 
To analyse the four endpoints above, an ANCOVA approach will be  used with a fixed factor for 
reversibility strata , and the baseline resu lt as a covariate. A ny missing data at Visit 6/Week [ADDRESS_382363] deviation. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 34  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382364]-Roger 
method will be used to e stimate the model de grees of freedom. 
Sample size calculation is ba sed on the number of  patients with  available data at Visit 6/week 4 
included in the analysis, therefore any assessment of sample si ze based on MMRM should also 
consider the drop-out rat e observed in the study. 
 
The MMRM model will use the square root of variance representin g Visit 6/Week [ADDRESS_382365] ing to actual treatment received, 
and summarized for SAF set. 
 
AEs will be coded using the MedD RA central coding dictionary, V ersion 22.0. 
 
Treatment emergent adverse events (TEAEs) are defined as all AE s which start after the first 
dose of study treatment or star t prior to first dose of study t reatment and wors en, based on the 
investigator’s assessment of s everity, on or after first dose o f study treatment. 
 
Non-treatment emergent adverse ev ents (non-TEAEs) are defined a s AEs that start prior to first 
dose of study treatment and end pr ior to first dose of study tr eatment, or do not  worsen, based on 
the investigator’s assessment  of severity, on or after first do se of study treatment. 
 
In the case where it is not possi ble to define an AE as treatme nt emergent or not, the AE will be 
classified by [CONTACT_310848];  i.e. treatment emergent. 
 
If any AE records contain only par tial dates, the se will be han dled by [CONTACT_47915], a s described in 
the Appendix 2. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 35  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382366] one event in each of the categories 
listed below will be pr ovided as specified i n the templates. In  addition, the numbe r of patients 
with each of the following AE events will be presented by [CONTACT_2946] a nd PT and summarized by 
[CONTACT_1570]: 
x TEAE 
x TEAEs leading to discontinua tion of study treatment 
x TEAEs causally related to study treatment 
x TEAEs by [CONTACT_764] 
x Serious TEAEs 
x Serious TEAEs causally rel ated to study treatment 
x Serious TEAEs by [CONTACT_764] 
x Serious TEAEs leading to discon tinuation of study treatment 
x TEAEs with an outcome of death 
AEs will be identified by [CONTACT_10540]  ‘Adverse Events’ page of th e eCRF. Listings will include 
TEAEs and Non-TEAEs. 
17.1.1.  Severity 
Severity is classed a s mild/ moderate/ seve re. TEAEs starting a fter the first dose of study 
treatment with a missing severit y will be classified as severe.  If patient reports a TEAE more 
than once within that SOC/ PT, the  AE with the worst-case sever ity will be used in the 
corresponding severity summaries. 
17.2. Laboratory Evaluations 
Results from the central labor atory will be included in the rep orting of this study for 
Hematology, Blood Chemistry, Urina lysis and Viral Serology. Mea surements and timepoints for 
each laboratory assessmen t can be found in Table 3. 
 
Presentations will use standa rd international (SI) Units. 
The handling of re-tests and unsch eduled measurements is detail ed in Section 6.3. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 38  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
ܴܴ( msec ) =  1000 כ 60 
ܴܪ( ݉݌ܾ ) 
x Fridericia’s Correction (msec) 
ܨܿܶܳ(  msec )  =  ܶܳ( ݏ݉ )
3 ݏ݉ ξܴܴ1000 
17.4. Vital Signs 
The following Vital Signs measurem ents will be reported for thi s study: 
x Supi[INVESTIGATOR_310827] (mmHg) 
x Supi[INVESTIGATOR_310828] B lood Pressure (mmHg) 
x Supi[INVESTIGATOR_310829] (bpm) 
x Body weight (kg) 
x BMI (kg/m2) 
 
Blood pressure and Pulse Rate are measured in a following way: 
x Screening 
x Day 1 and Week 4 (End of Study) – pre-dose and [ADDRESS_382367]-dose 
x Week 1 – Week 3 – pre-dose and 30 minutes, 1, 2 and 3 hours pos t-dose 
BMI is calculated at Screen ing and End of Study visit using hei ght measured at Screening, and 
body weight measured at Screening and End of Study visit. 
The following summaries will be pr ovided for Vital Signs data, summarised by [CONTACT_1570]: 
x Change from baseline table by [CONTACT_310849] t-dose time-point  of collectio n for continuous variables 
x Shift tables representing cha nges from Normal/ Low/ High, defin ed in the Table 5. 
x Listings of patients meeting mar kedly abnormal criteria after t he first dose 
 
A plot over time will be presente d for all vital signs by [CONTACT_310850]. 
17.4.1. Vital Signs Markedl y Abnormal Criteria 
Markedly abnormal quantitative v ital signs measurements will be  identified in accordance with 
the predefined markedly abnor mal criteria found in Table 5. 

PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 40  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382368]-PRO Initiative . October 2014. 
<http://www.ema.europa.eu/docs/en_GB/document_library/Other/201 5/04/WC500185444.pdf>. 
ICH. "E9 Statistical Principle s for Clinical Trials." 1998. 
Jones, P W, F H Quirk and C M Baveystock. "The St George's Resp iratory Questionnaire." Respi[INVESTIGATOR_33593] (1991): 
25-31. 
Jones, [CONTACT_310855]. "ST GEORGE’S RESPI[INVESTIGATOR_310830] F OR COPD PATIENTS (SGRQ-C) MANUAL." April 
2012. <http://www.healthstatus.sgul.ac.uk/SGRQ_download/sgrq-c- manual-april-2012.pdf>. 
SAS Institute, Inc. SAS Procedures Guide, version 8 . Cary, NC: SAS Institute, 1999. 
The European Agency for the Evaluation of Medicinal Products. " Points to consider on multiplicity issues in clinical 
trials." 2002. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 41  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
APPENDIX 1. PROGRAMMING CONVENTIONS FOR OUTPUTS 
Dates & Times
Depending on data availabl e, dates and times w ill take the form  yyyy-mm-ddThh:mm:ss. 
Spelling Format 
English US. 
Presentation of Treatment Groups 
For outputs, treatment groups will  be represented as follows an d in that order: 
 
Treatment Group For Tables, Listings and Figures 
RPL554 0.375 mg RPL554 0.375 mg 
RPL554 0.75 mg RPL554 0.75 mg 
RPL554 1.5 mg RPL554 1.5 mg 
RPL554 3 mg RPL554 3 mg 
Placebo Placebo 
Decimal Places 
The decimal places for this study will use the following rules,  unless otherwise stated. 
Value = x dp Mean = x+[ADDRESS_382369] Deviation = x+2 dp Median = x+1 dp Q1/Q3 = x+1 dp Minimum/Maximum = x dp 
CI = x+1 dp 
 
For spi[INVESTIGATOR_310831]: 
x Values in litres = 3dp 
x Values in millilitres = 0dp 
x Percentage values = 1dp 
 
P-values will be presented to 4dp. 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 42  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
Presentation of Visits 
For outputs, visits will be repre sented as follows and in that order, unless otherw ise specified: 
 
Long Name (default) Short Name 
[CONTACT_183172]-Screening Pre-Screening 
Screening Screening 
Baseline Baseline 
Day 1 Day 1 
Week 1 Week 1 
Week 2 Week 2 
Week 3 Week 3 
Week 4 Week 4 
Follow-up FUP 
Listings 
All listings will be ordered by [CONTACT_182363] (unless otherwise  indicated in the  template): 
x Randomized treatment gr oup (or treatment received if it’s a saf ety output) 
x Centre-patient ID, 
x Treatment day (where applicable), 
x Date and time (if applicable), 
x For listings where non-randomize d patients are included, these will appear in a category 
after the randomized treatment  groups labelled ‘Not Randomized’ . 
Tables 
All tables presenting multiple events that map to a SOC and PT will be counted only once, per 
unique patient, for inc idence counts. Events will be presented in descending frequency of SOC 
and PT (unless otherwise i ndicated in the template). 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 46  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382370] possi ble date (i.e. last day 
of month if day unknown or 31st December if day and month are unknown), then: If stop date <= study med sta rt date, assign as prior 
If stop date > study med s tart date, assign as 
concomitant Cannot be assigned as ‘post treatment’ 
Missing Assign as concomitant
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 47  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
APPENDIX 3. REVERSIBILITY ROUNDING CRITERIA 
 
 
  
 

PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 48  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382371] feel c ongested today? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
4.Extremely 
2. How often did you cough today? 0.Not at all 
1.Rarely 
2.Occasionally 
3.Frequently 
4.Almost constantly 
3. How much mucus (phl egm) did you bring up when 
coughing today? 0.None at all 
1.A little 
1.Some 
2.A great deal 
3.A very great deal 
4. How difficult was it to bring up mucus (phlegm) 
today? 0.Not at all 
1.Slightly 
2.Moderately 
3.Quite a bit 
4.Extremely 
5. Did you have chest discomfort today? 0.Not at all 
1.Slight 
2.Moderate 
3.Severe 
4.Extreme
6. Did your chest feel tight today? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
4.Extremely 
7. Were you breathless today? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
4.Extremely 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 49  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
8.Describe how breathless you were today 0.Unaware of breathlessness 
1.Breathless during strenuous activity 
2.Breathless during light activity 
3.Breathless when washing or dressing 
3.Present when resting 
9. Were you short of breat h today when performing 
your usual personal care ac tivities like washing or 
dressing? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
3.Extremely 
4.Too breathless to do these 
10. Were you short of breath today when performing 
your usual indoor activities like cleaning or household work? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
3.Extremely 
3.Too breathless to do these 
11. Were you short of breath today when performing 
your usual activities outside  the home such as yard 
work or errands? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
3.Extremely 
3.Too breathless to do these 
12. Were you tired or weak today? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
4.Extremely 
13. Last night, was your sleep disturbed? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
4.Extremely 
14. How scared or worrie d were you about your lung 
problems today? 0.Not at all 
1.Slightly 
2.Moderately 
3.Severely 
3.Extremely 
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 50  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382372] Total 
Score 
0 0 26 50
1 8 27 51
2 13 28 52
31 7 2 9 5 3
4 20 30 54
5 23 31 55
6 25 32 57
7 27 33 58
8 28 34 59
9 30 35 60
10 31 36 61
11 33 37 63
12 34 38 64
13 36 39 65
14 37 40 67
15 38 41 68
16 39 42 70
17 40 43 72
18 41 44 73
19 42 45 75
20 43 46 77
21 44 47 80
22 46 48 83
23 47 49 87
24 48 50 92
25 49 51 100
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 51  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
APPENDIX 6. SGRQ-C I TEM WEIGHTS 
 
Question Answers Weight 
Part 1
Question 1: I cough  
Most days 80.[ADDRESS_382373] infections 28.1
Not at all 0.0 
Question 2: I bring up phlegm (sputum)  
Most days 76.[ADDRESS_382374] infections 30.2 
Not at all 0.0 
Question 3: I have shortness of breath 
Most days 87.2 
Several days 50.3 
Not at all 0.0 
Question 4: I have attacks of wheezing  
Most days 86.[ADDRESS_382375] infections 36.4 
Not at all 0.0 
Question 5: How many attacks of chest 
trouble have you had  
3 or more 80.1 
1 or 2 attacks 52.3 
None 0.0 
Question 6: How often do you have good days (with little c hest trouble)  
None 93.[ADDRESS_382376] are good 38.5 
Every day 0.0 
Question 7: If you have a wheeze, is it 
worse in the morning?  
No 0.0 
Yes 62.0 
Part 2
  
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 52  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, 2018 IQVIA. All rights reser ved. The contents of this document are confidential and proprie tary 
to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.  
  
Question 8: How would you describe your 
chest condition? The most important problem I have 82.9 
Causes me a few problems 34.6 
Causes no problem 0.0 
Question 9: Questions about what 
activities usually make you feel breathless 
Getting washed or dressed 82.8 
Walking around the home 80.2 
Walking outside on the level 81.4 
Walking up a flight of stairs 76.1 
Walking up hills 75.1 
Question 10: More questions about your cough and breathlessness  
My cough hurts 81.1 
My cough makes me tired 79.1 
I get breathless when I talk 84.5 
I get breathless when I bend over 76.8 
My cough or breathing disturbs my sleep 87.9 
I get exhausted easily 84.0 
Question 11: Questions about other 
effects your chest  trouble may have on 
you  
My cough or breathing is embarrassing in public 74.[ADDRESS_382377] 89.9 
Exercise is not safe for me 75.7 
Everything seems too much of an 
effort 84.5 
Question 12: Questions about how 
activities may be affected by [CONTACT_310851]  
I take a long time t o get washed or 
dressed 74.2 
I cannot take a bath or shower, or I 
take a long time 81.0 
I walk more slowly than other people, 
or I stop for rests 71.7
PROTOCOL No. RPL554-CO-205 
Statistical Analysis Plan Page 53  of 
Document: 
Author: …\Verona_Pharma\RPL554\BZA48916\Biostatistics\Documentation\SAP \Verona CO-205 SAP v1.0 
 Version Number: 
Version Date: 
Reference: V1.0 
05DEC2019 
CS_WI_BS005 Template No.: CS_TP_BS016 Revision 5 
Effective Date: 01Apr2018 
Copyright © 2009, 2010, 2012, 2016, [ADDRESS_382378] to stop 
or slow down 72.3 
My breathing makes it difficult to do 
things such as walk up hills, carry things up stairs, light gardening such as weeding, dance, play bowls or play golf 74.5 
My breathing makes it difficult to do 
things such as carry heavy loads, dig the garden or shovel snow, jog or walk at 
5 miles per hour, pla y tennis or swim 71.4
Question 13: We would like to know how 
your chest trouble actually affects your daily life  
I cannot play sports or games 64.8 
I cannot go out for entertainment or recreation 79.8 
I cannot go out of the house to do the
shoppi[INVESTIGATOR_007] 81.0
I cannot do housework 79.1 
I cannot move far from my bed or 
chair 94.0 
Question 14: Tick the s tatement which 
you think best describe s how your chest 
affects you  
It does not stop me doing anything I would like to do 0.[ADDRESS_382379] of the things I 
would like to do 84.2 
It stops me doing everything I would 
like to do 96.7 
 